Reuters (subscription required): Hesham Abboud, assistant professor at the School of Medicine, discussed the safety and efficacy of current and emerging COVID-19 vaccines in MS patients, taking into consideration the impact of immunosuppressive or immunomodulatory disease-modifying therapies.
